Bavarian Nordic A/S announced that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus). As previously announced, the company is investigating the potential use of its core vaccine technology, MVA-B more
To use all functions of this page, please activate cookies in your browser.
